Measurement of plasma oxidized low-density lipoprotein and its clinical implications

Journal of Atherosclerosis and Thrombosis

Volumn 14, Issue 1, 2007, Pages 1-11

  Itabe, Hiroyuki ^a   Ueda, Makiko ^b  

^a SHOWA UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

AMI; ELISA; Monoclonal antibody; Oxidized low density lipoprotein

Indexed keywords

LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

BLOOD; CARDIOVASCULAR DISEASE; HUMAN; IMMUNOASSAY; REVIEW; TECHNIQUE;

CARDIOVASCULAR DISEASES; HUMANS; IMMUNOASSAY; LIPOPROTEINS, LDL; METHODS;

EID: 34249856730     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.14.1     Document Type: Review

References (58)

1. Witztum JL and Steinberg D; Role of oxidized low density lipoprotein in atherosclerosis. J Clin Invest, 1991; 88:1785-1792
2. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 1993; 362:801-809
3. Yamada Y, Doi T, Hamakubo T, and Kodama T: Scavenger receptor family proteins: Roles for atherosclerosis, host defense and disorders of the central nervous system. Cell Mol Life Sci, 1998; 54:628-640
4. Greaves DR and Gordon S: Recent insights into the biology of macrophage scavenger receptors. J Lipid Res, 2005; 46:11-20
5. Steinbrecher UP: Receptors for oxidized low density lipoprotein. Biochim Biophys Acta, 1999; 1436:279-298
6. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguschi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Horiuchi S, Takahashi K, Kruijt JK, van Berkel TJC, Steinbrecher UP, Ishibashi S, Maeda N, Gordon S, and Kodama T: A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature, 1997; 386:292-296
7. Nozaki S, Kashiwagi H, Yamashita S, Nakagawa T, Kostner B, Tomiyama Y, Nakata A, Ishigami M, Miyagwa J, Takemura K, Kurata Y, and Matsuzaw Y: Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest, 1996; 96:1859-1865
8. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, and Silverstein RL: Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest, 2000; 9105:1049-1056
9. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, and Masaki T: An endothelial receptor for oxidized low-density lipoprotein. Nature, 1997; 386:73-77
10. Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imanaka T, and Takano T: A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholine and polypeptides. J Biol Chem, 1994; 269:15274-15279
11. Itabe H, Yamamoto H, Imanaka T, Suzuki M, Kawai Y, Nakagawa Y, Suzuki A, and Takano T: Oxidized phosphatidylcholines that modify proteins. Analysis by anti-oxidized low density lipoprotein monoclonal antibody. J Biol Chem, 1996; 271:33208-33217
12. Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, Sanaka T, Hata Y, and Takano T: Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res, 1996; 37:45-53
13. Kohno H, Sueshige N, Oguri K, Izumidate H, Masunari T, Kawamura M, Itabe H, Takano T, Hasegawa A, and Nagai R: Simple and practical sandwich-type enzyme immunoassay for human oxidatively modified low density lipoprotein using antioxidized phosphatidylcholine monoclonal antibody and antihuman apolipoprotein-B antibody. Clin Biochem, 2000; 33:243-253
14. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lasaffre E, Vanrenterghem Y, and Collen D: Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost, 1996; 76:663-669
15. Penny WF, Ben-yehuda O, Kuroe K, Long J, Bond A, Bhargava V, Peterson JF, McDaniel M, Julicano J, Witztum JL, Ross Jr. J, and Peterson KL: Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: Heterogeniety of segmental response and correlation with plasma-oxidized low density lipoprotein. J Am Coll Cardiol, 2001; 37:766-774
16. Fang JC, Kinlay S, Bhargava V, Hikita H, Witztum JL, Selwyn AP, and Ganz P: Circulating autoantibodies to oxidized LDL correlate with impaired coronary endothelial function after cardiac transplantation. Arterioscler Thromb Vasc Biol, 2006; 26:2044-2048
17. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otuska M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, and Becker AE: Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation, 2001; 103:1955-1960
18. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, and Nagahiro S: Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol, 2002; 22:1649-1654
19. Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, Juliano J, and Witztum JL: Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol, 2003; 41:360-730
20. Kayo S, Ohsawa M, Ehara S, Naruko T, Ikura Y, Hai E, Yoshimi N, Shirai N, Tsukamoto Y, Itabe H, Higuchi K, Arakawa T, and Ueda M: Oxidized low density lipoprotein levels circulating in plasma and deposited in the tissues: Comparison between Helicobacter pylori-associated gastritis and acute myocardial infarction. American Heart Journal, 2004; 148:818-825
21. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, and Van de Werf F: Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol, 2001; 21:844-1848
22. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita I, and Nagai R: Circulating oxidized modified low density lipoprotein levels: A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol, 2000; 20:2243-2247
23. Holvoet P, Stassen JM, Van Cleemput J, Collen D, and Vanhaecke J: Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol, 1998; 18:100-107
24. Binder CJ, Hörkkö S, Dewan A, Chang MK, Kieu EP, Goodyear CS, Shaw PX, Palinski W, Witztum JL, and Silverman GJ: Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med, 2003; 9:736-743
25. Chang MK, Binder CJ, Torzenwski M, and Witztum JL: C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA, 2002; 99:13043-13048
26. Matsuura E, Kobayashi K, Tabuchi M, and Lopez LR: Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res. 2006; 45:466-486
27. Holvoet P, Macy E, Landeloos M, Jones D, Nancy JS, Van de Werf F, and Tracy RP: Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin Chem, 2006; 52:760-764
28. Suzuki T, Kohno H, Hasegawa A, Toshima S, Amaki T, Kurabayashi M, Nagai R, Suzuki T, Amaki T, Nagai R, Hasegawa A, Toshima S, Kurabayashi MH, Shimada K, Nakamura H, Teramoto T, Yamaguchi H, Nishiyama S, Takahashi H, Michishita I, Sugano Z, and Konishi K: Clinical Trial of Oxidized LDL (CTOL) investigators: Diagnostic implications of circulating oxidized low density lipoprotein levels as a biochemical risk marker of coronary artery disease. Clin Biochem, 2002; 35:347-353
29. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, and Berger PB: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Eng J Med, 2005; 353:46-57
30. Nielsen LB: Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Atheroscler, 1999; 143:229-243
31. Itabe H, Mori M, Fujimoto Y, Higashi Y, and Takano T: Minimally modified LDL is an oxidized LDL enriched with oxidized phosphatidylcholines. J Biochem, 2003; 134:459-465
32. Ziouzenkova O, Sevanian A, Abuja PM, Ramos P, and Esterbauer H: Free Radic Biol Med, 1998; 24:607-623
33. Neužil J, Thomas SR, and Stocker R: Requirement for, promotion, or inhibition by α-tocopherol of radical-induced initiation of plasma lipoprotein lipid peroxidation. Free Radic Biol Med, 1997; 22:57-71
34. Stocker R: Lipoprotein oxidation: mechanistic aspects, methodological approaches and clinical relevance. Cur Op Lipidl, 1994; 5:422-433
35. Tsimikas S, Witzutum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, and Schwartz GG: High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation, 2004; 110:1406-1412
36. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, and Collen D: Oxidized LDL and Malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation, 1998; 98:1487-1494
37. Segev A, Strauss BH, Witztum JL, Lau HK, and Tsimikas S: Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markets to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. Am Heart J, 2005; 150:1007-1014
38. Uno M, Kitazato KT, Nishi K, Itabe H, and Nagahiro S: Raised plasma oxidised LDL in acute cerebral infarction. J Neurol Neurosurg Psychiatry, 2003; 74:312-316
39. Uno M, Harada M, Takimoto O, Kitazato KT, Suzue A, Yoneda K, Morita N, Itabe H, and Nagahiro S: Elevation of plasma oxidized LDL in acute stroke patients is associated with ischemic lesions depicted by DWI and predictive of infarct enlargement. Neurol Res, 2005; 27:94-102
40. Uno M, Kitazato KT, Suzue A, Matsuzaki K, Harada M, Itabe H, and Nagahiro S: Inhibition of brain damage by edaravone, a free radical scavenger, can be monitored by plasma biomarkers that detect oxidative and astrocyte damage in patients with acute cerebral infarction. Free Radic Biol Med, 2005; 39:1109-1116
41. Holvoet P, Van Cleemput J, Collen D, and Vanhaecke J: Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol, 2000; 20:698-702
42. Tamai O, Matsuoka H, Itabe H, Wada Y. Kohno K, and Imaizumi T: Single LDL apherasis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation, 1997; 95:76-82
43. Ehara S, Ueda M, Naruko T, Haze K, Matsuo T, Ogami M, Ikura Y, Itabe H, Komatsu R, Yoshiyama M, Takeuchi K, and Yoshikawa J: Pathophysiological role of oxidized low-density lipoprotein in plaque instability in coronary artery diseases J Diabetes Complications, 2002; 16:60-64
44. Ujihara N, Sakka Y, Takeda M, Hirayama M, Ishii A, Tomonaga O, Babazono T, Takahashi C, Yamashita K, and Iwamoto Y: Association between plasma oxidized low-density lipoprotein and diabetic nephropathy. Diabetes Res Clin Pract, 2002; 58:109-112
45. Miyazaki H, Matsuoka H, Itabe H, Usui M, Ueda S, Okuda S, and Imaizumi T: Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation, 2000; 101:1002-1006
46. Matsumoto T, Takashima H, Ohira N, Tarutani Y, Yasuda Y, Yamane T, Matsuo S, and Horie M: Plasma level of oxidized low-density lipoprotein is an independent determinant of coronary macrovasomotor and microvasomotor responses induced by bradykinin. J Am Coll Cardiol, 2004; 44:451-457
47. Naruko T, Ueda M, Ehara S, Itoh A, Haze K, Shirai N, Ikura Y, Ohsawa M, Itabe H, Kobayashi Y, Yamagishi H, Yoshiyama M, Yoshikawa J, and Becker AE: Persistent high levels of plasma oxidized low-density lipoprotein after acute myocardial infarction predict stent restenosis. Arterioscler Thromb Vasc Biol, 2006; 26:877-883
48. Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A, Curtiss LK, Witztum JL, and Strauss BH: Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a). Short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation, 2004; 109:3164-3170
49. Inami S, Okamatsu K, Takano M, Takagi G, Sakai S, Sano J, and Mizuno K: Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia. Jpn Heart J, 2004; 45:969-975
50. Hulthe J and Faberberg B: Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines. Arterioscler Thromb Vasc Biol, 2002; 22:1162-1167
51. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, Goodpaster B, and Harris TB: The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-fanctioning elderly people in the health, aging, and body composition cohort. Diabetes, 2004; 53:1068-1073
52. Shimada K, Mokuno H, Matsunaga E, Miyazaki T, Sumiyoshi K, Miyauchi K, and Daida H: Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atheroscler, 2004; 174:343-347
53. Meisinger C, Baumert J, Khuseyinova N, Loewel H, and Koenig W: Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease event in apparently healthy, middle-aged men from the general population. Circulation, 2005; 112:651-657
54. Braun S, Ndrepepa G, von Beckerath N, Mechilli J, Gorchakova O, Vogt W, Schömig A, and Kastrati A: Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting. Am Heart J, 2005; 150:550-556
55. Sjogren P, Basu S, Rosell M, Silveira A, de Faire U, Vessby B, Hamsten A, Hellenius ML, and Fisher RM: Measures of oxidized low-density lipoprotein and oxidative stress are not related and not elevated otherwise healthy men with the metabolic syndrome. Arterioscler Thromb Vasc Biol, 2005; 25:2580-2586
56. Tabuchi M, Inoue K, Usui-Kataoka H, Kobayashi K, Teramoto M, Takasugi K, Shikata K, Yamamura M, Ando K, Nishida K, Kasahara J, Kume N, Lopez LR, Mitsudo K, Nobuyoshi M, Yasuda T, Kita T, Makino H, and Matsuura E: The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res, 2007; Epub ahead of print
57. Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, Tanaka M, Ueda A, Kominami G, Kambara H, Kimura T, and Kita T: Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel market for early diagnosis. Circulation, 2005; 112:812-818
58. Hirano T, Ito Y, Koba S, Toyoda M, Ikejiri A, Saegusa H, Yamazaki J, and Yoshino G: Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol, 2004; 24:558-563